Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) General Counsel Jason B. Shandell sold 9,478 shares of the business’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $20.67, for a total value of $195,910.26. Following the completion of the transaction, the general counsel now directly owns 159,947 shares in the company, valued at approximately $3,306,104.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Amphastar Pharmaceuticals stock opened at $20.16 on Friday. The company has a current ratio of 2.06, a quick ratio of 1.41 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $943.27 million, a price-to-earnings ratio of 87.65, a price-to-earnings-growth ratio of 2.30 and a beta of 1.37. Amphastar Pharmaceuticals Inc has a 52 week low of $14.40 and a 52 week high of $25.43.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Tuesday, March 12th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The company had revenue of $89.69 million for the quarter, compared to analyst estimates of $75.46 million. Amphastar Pharmaceuticals had a positive return on equity of 3.17% and a negative net margin of 1.96%. Research analysts anticipate that Amphastar Pharmaceuticals Inc will post 0.35 earnings per share for the current year.

A number of equities analysts have commented on the company. Zacks Investment Research raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 27th. TheStreet raised Amphastar Pharmaceuticals from a “c+” rating to a “b-” rating in a research note on Friday, January 11th. BidaskClub lowered Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, February 25th. Piper Jaffray Companies lowered Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $24.00 to $23.00 in a research note on Wednesday, March 13th. Finally, Needham & Company LLC lowered Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating and set a $22.20 price objective on the stock. in a research note on Wednesday, March 13th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $23.73.

A number of institutional investors have recently bought and sold shares of AMPH. BlackRock Inc. raised its position in shares of Amphastar Pharmaceuticals by 4.7% during the third quarter. BlackRock Inc. now owns 5,987,805 shares of the company’s stock worth $115,205,000 after acquiring an additional 267,622 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Amphastar Pharmaceuticals by 7.9% during the third quarter. Dimensional Fund Advisors LP now owns 1,909,883 shares of the company’s stock worth $36,746,000 after acquiring an additional 140,350 shares during the last quarter. Teachers Advisors LLC raised its position in shares of Amphastar Pharmaceuticals by 0.7% during the third quarter. Teachers Advisors LLC now owns 566,984 shares of the company’s stock worth $10,909,000 after acquiring an additional 4,194 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Amphastar Pharmaceuticals by 6.7% during the fourth quarter. Bank of New York Mellon Corp now owns 447,128 shares of the company’s stock worth $8,898,000 after acquiring an additional 28,225 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Amphastar Pharmaceuticals by 9.5% during the fourth quarter. Geode Capital Management LLC now owns 425,301 shares of the company’s stock worth $8,462,000 after acquiring an additional 36,784 shares during the last quarter. 47.57% of the stock is currently owned by institutional investors.

WARNING: “Amphastar Pharmaceuticals Inc (AMPH) General Counsel Jason B. Shandell Sells 9,478 Shares” was originally posted by Marea Informative and is the sole property of of Marea Informative. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.mareainformativa.com/news/2019/04/21/amphastar-pharmaceuticals-inc-amph-general-counsel-jason-b-shandell-sells-9478-shares.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Featured Story: Moving Average Convergence Divergence (MACD)

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.